BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19350357)

  • 1. Disparities in the survival improvement of recurrent breast cancer.
    Anan K; Mitsuyama S; Koga K; Tanabe R; Saimura M; Tanabe Y; Watanabe M; Suehara N; Matsunaga H; Nishihara K; Abe Y; Nakano T; Tamae K; Ono M; Toyoshima S
    Breast Cancer; 2010; 17(1):48-55. PubMed ID: 19350357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locoregional recurrence of breast cancer: a retrospective comparison of treatment methods.
    Skowronek J; Piotrowski T
    Neoplasma; 2002; 49(6):426-31. PubMed ID: 12584593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
    Carreño G; Del Casar JM; Corte MD; González LO; Bongera M; Merino AM; Juan G; Obregón R; Martínez E; Vizoso FJ
    Breast Cancer Res Treat; 2007 Mar; 102(1):61-73. PubMed ID: 16850244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
    Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distant metastasis in triple-negative breast cancer.
    Tseng LM; Hsu NC; Chen SC; Lu YS; Lin CH; Chang DY; Li H; Lin YC; Chang HK; Chao TC; Ouyang F; Hou MF
    Neoplasma; 2013; 60(3):290-4. PubMed ID: 23373998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is breast cancer survival improving?
    Giordano SH; Buzdar AU; Smith TL; Kau SW; Yang Y; Hortobagyi GN
    Cancer; 2004 Jan; 100(1):44-52. PubMed ID: 14692023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative margin status improves local control in conservatively managed breast cancer patients.
    Obedian E; Haffty BG
    Cancer J Sci Am; 2000; 6(1):28-33. PubMed ID: 10696736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor.
    Babiera GV; Rao R; Feng L; Meric-Bernstam F; Kuerer HM; Singletary SE; Hunt KK; Ross MI; Gwyn KM; Feig BW; Ames FC; Hortobagyi GN
    Ann Surg Oncol; 2006 Jun; 13(6):776-82. PubMed ID: 16614878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.